PMID- 36643795
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230117
IS  - 2667-0895 (Electronic)
IS  - 2667-0909 (Print)
IS  - 2667-0895 (Linking)
VI  - 50
DP  - 2022 Dec
TI  - The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic 
      significance in statin-naive patients with acute ST elevation myocardial 
      infarction.
PG  - 50-56
LID - 10.1016/j.athplu.2022.09.002 [doi]
AB  - BACKGROUND AND AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) 
      circulates as mature and furin-cleaved forms, but their biological functions are 
      uncertain. We investigated whether their levels associate with prognosis in 
      patients with acute ST elevation myocardial infarction (STEMI). METHODS: We 
      enrolled 160 statin-naive patients with acute STEMI and followed for 3 years. 
      PCSK9 subtype levels were determined by an enzyme-linked immunosorbent assay 
      before and at five timepoints up to 48 h after emergent coronary intervention. 
      The occurrence of coronary and cardiac events was compared between subjects 
      stratified by the PCSK9 level. RESULTS: One hundred and twenty-six patients 
      completed 3 years of follow-up. In the acute phase, both PCSK9 subtype levels 
      decreased, and thereafter increased from 6 to 48 h (mature: from 198 +/- 67 to 
      334 +/- 116 ng/mL, furin-cleaved: from 20 +/- 7 to 39 +/- 16 ng/mL, both p < 0.01). 
      Major cardiac events occurred in 46 patients. The furin-cleaved/mature PCSK9 
      ratio at 48 h after coronary intervention predicted the likelihood of 
      experiencing of events; patients in the third tertile had lower event-free 
      survival than those in the first and second tetiles in Kaplan-Meier analysis 
      (p = 0.004). Multivariate Cox regression analysis revealed that this ratio had a 
      greater impact (HR: 1.92; 95% CI: 1.06-3.45, p = 0.03) on events than other known 
      atherosclerosis risk factors. CONCLUSIONS: The furin-cleaved/mature PCSK9 ratio 
      was associated with 3-year cardiovascular events in statin-naive patients with 
      acute STEMI, suggesting a potential link between furin cleavage process of PCSK9 
      and its effect on prognosis. (249 words).
CI  - (c) 2022 The Authors.
FAU - Sawaguchi, Jun
AU  - Sawaguchi J
AD  - Department of Cardiology, 1-1 Daigaku, Uchinada, 920-0293, Japan.
FAU - Saeki, Yasuhiko
AU  - Saeki Y
AD  - Department of Cardiology, 1-1 Daigaku, Uchinada, 920-0293, Japan.
FAU - Oda, Minako
AU  - Oda M
AD  - Department of Cardiology, 1-1 Daigaku, Uchinada, 920-0293, Japan.
FAU - Takamura, Taka-Aki
AU  - Takamura TA
AD  - Department of Cardiology, 1-1 Daigaku, Uchinada, 920-0293, Japan.
FAU - Fujibayashi, Kosuke
AU  - Fujibayashi K
AD  - Department of Cardiology, 1-1 Daigaku, Uchinada, 920-0293, Japan.
FAU - Wakasa, Minoru
AU  - Wakasa M
AD  - Department of Cardiology, 1-1 Daigaku, Uchinada, 920-0293, Japan.
FAU - Akao, Hironobu
AU  - Akao H
AD  - Department of Cardiology, 1-1 Daigaku, Uchinada, 920-0293, Japan.
FAU - Kitayama, Michihiko
AU  - Kitayama M
AD  - Trans-catheter Cardiovascular Therapeutics, Kanazawa Medical University, 1-1 
      Daigaku, Uchinada, 920-0293, Japan.
FAU - Kawai, Yasuyuki
AU  - Kawai Y
AD  - Department of Cardiology, 1-1 Daigaku, Uchinada, 920-0293, Japan.
FAU - Kajinami, Kouji
AU  - Kajinami K
AD  - Department of Cardiology, 1-1 Daigaku, Uchinada, 920-0293, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220930
PL  - Netherlands
TA  - Atheroscler Plus
JT  - Atherosclerosis plus
JID - 9918249514806676
PMC - PMC9833232
OTO - NOTNLM
OT  - Acute myocardial infarction
OT  - Prognosis
OT  - Proprotein convertase subtilisin/kexin type 9 (PCSK9)
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/01/17 06:00
MHDA- 2023/01/17 06:01
PMCR- 2022/09/30
CRDT- 2023/01/16 02:47
PHST- 2022/05/26 00:00 [received]
PHST- 2022/09/09 00:00 [revised]
PHST- 2022/09/26 00:00 [accepted]
PHST- 2023/01/16 02:47 [entrez]
PHST- 2023/01/17 06:00 [pubmed]
PHST- 2023/01/17 06:01 [medline]
PHST- 2022/09/30 00:00 [pmc-release]
AID - S2667-0895(22)00051-7 [pii]
AID - 10.1016/j.athplu.2022.09.002 [doi]
PST - epublish
SO  - Atheroscler Plus. 2022 Sep 30;50:50-56. doi: 10.1016/j.athplu.2022.09.002. 
      eCollection 2022 Dec.